Headache: challenging conventional wisdom

The Lancet Neurology

Volumn 8, Issue 1, 2009, Pages 12-14

  Dodick, David W ^a   Schwedt, Todd ^b  

^a MAYO CLINIC   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARBITURIC ACID DERIVATIVE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; TELCAGEPANT; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ARTICLE; DRUG MECHANISM; HEADACHE; HUMAN; MIGRAINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SPREADING CORTICAL DEPRESSION; TRANSFORMED MIGRAINE; UNSPECIFIED SIDE EFFECT;

EID: 57149098581     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70275-8     Document Type: Note

References (5)

1. Bigal M.E., Sarrono D., Buse D., Scher A., Stewart W.F., and Lipton R.B. Acute migraine mediactions and evolution for episodic to chronic migraine: a longitudinal population-based study. Headache 48 (2008) 1157-1168
2. Schmitz N., Admiraal-Behloul F., Arkink E.B., et al. Attack frequency and disease duration as indicators for brain damage in migraine. Headache 48 (2008) 1044-1055
3. Denuelle M., Fabre N., Payoux P., Chollet F., and Geraud G. Posterior cerebral hypoperfusion in migraine without aura. Cephalalgia 28 (2008) 856-862
4. Schoonman G.G., van der Grond J., Kortmann C., van der Geest R.J., Terwindt G.M., and Ferrari M.D. Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain 131 (2008) 2192-2200
5. Ho T.W., Ferrari M.D., Dodick D.W., et al. Acute antimigraine efficacy and tolerability of the novel oral CGRP receptor antagonist MK-0974: a phase III clinical trial versus placebo and zolmitriptan. Headache 48 (2008) S7-S8